CW May 2003
Volume 12Issue Number 5 May 2003 ISSN 10593802 Thalidomide Analogue to Treat Myelodysplastic SyndromesRevimid™, an analogue of thalidomide that belongs to a group of immunomodulatory drugs, is shown to be effective in treating myelodysplastic syndromes. This blood cell disorder can lead to cancer if not treated.
Go to Previous Page Go to Next Page Source & Additional Reading A. List et al., Data Presented at the Seventh International Symposium on Myelodysplastic Syndromes recently held in Paris, May 15, 2003. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW May 2003Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
